AstraZeneca Plc

Equity

What's this?

Price (GBX)

8,505.00 0.29%

AZNORD SHS $0.25

Track

5 more instruments

Open / Last close

8,430.00 / 8,505.00

High / Low

8,647.00 / 8,413.00

Bid / Offer

8,487.00 / 8,491.00

Turnover

£109,862,590.30

Special Condition: -

Trading Status: Market Close

FTSE 100

As at 12.07.20 07:17:20 - All data delayed at least 15 minutes

5 more instruments

AstraZeneca Plc instruments

Select instrument to view

Equity (1)

Code	Instrument name	Price	Change	Type	Documentation
AZN	ORD SHS $0.25	8,505.00 GBX	0.29%	Equity	-

Bonds (5)

Code	Instrument name	Price	Maturity	Type	Documentation
35BR	0.750% NTS 12/05/24	- EUR	12.05.24	Bonds	-
35BZ	1.250% NTS 12/05/28	- EUR	12.05.28	Bonds	-
35CA	0.250% NTS 12/05/21	- EUR	12.05.21	Bonds	-
43ER	0.875% NTS 24/11/21	- EUR	24.11.21	Bonds	-
50UC	5.75% NTS 13/11/31	144.00 GBP	13.11.31	Bonds	-

Price information

What's this?

Open price

8,430.00

Previous close price / date

8,505.00 / 10 July 2020

Volume

1,520,360

Turnover

£109,862,590.30

52 week range

6,221.00 / 9,004.00

YTD return

11.03

1 year return

34.49

Instrument information

What's this?

Instrument market cap (£m)

111,280.59

Earnings per share

1.03

Dividend (yield)

2.79 %

Issue date

13 January 2006

ISIN

GB0009895292

SEDOL

0989529

Market identifier code (MIC)

XLON

Country of share register

Market segment

SET1

Trading service

SETS

Last 5 trades

What's this?

Show me more trades

Date	Time	Price	Currency	Volume	Trade Value	Trade type	Trade flag	MIC
10.07.20	17:15:36	8,505.00	GBX	10,519	894,640.95	Off-Book	TNCP	XOFF
10.07.20	17:50:32	8,539.74	GBX	13,080	1,116,998.25	Off-Book	TNCP	XOFF
10.07.20	11:48:51	8,603.05	GBX	42	3,613.28	Off-Book	TNCP	XOFF
10.07.20	18:09:45	991.40	SEK	775	768,335.00	Off-Book	TNCP	XOFF
10.07.20	18:09:45	991.40	SEK	235	232,979.00	Off-Book	TNCP	XOFF

Upcoming Events

from AstraZeneca Plc

AstraZeneca results and presentations

March 31st 2020, 11:00:00pm

Duration: + Add to my Calendar

Equity Research

from AstraZeneca Plc

AstraZeneca Gilead union is hard to digest

According to market rumours, AstraZeneca informally approached Gilead for a possible merger last month – if the deal goes ahead, it would be the biggest transaction in pharma industry to date. However, the strategic rationale for the deal appears limited – AstraZeneca and Gilead have ...

View report

Euphoric Q1 20 sales growth, despite high Chinese exposure

Despite being China-heavy, AstraZeneca had a superb start to 2020, with Q1 sales CER growth of 17%. While Oncology was once again the key growth driver, reasonable (but possibly transient) support came from ‘Respiratory + Immunology’, and New CVRM. However, a key question is – h ...

View report

SP Angel Healthcare Conditions

Novacyt (NCYT.L): Agreements struck with Bruker and Yourgene | Polarean Imaging (POLX.L): Change of General Meeting Venue | Silence Therapeutics (SLN.L): Strategic collaboration with AstraZeneca (AZN.L)

View report

Q4 (growth) hits a wall; 2019-nCoV overshadows the near term

AstraZeneca’s Q4 results were disappointing, both from a sales growth and profitability perspective. While Oncology and CVRM (to some extent) remain the key growth drivers, growing competition is concerning. Moreover, with the 2019-nCoV scare, near-term business visibility has hit a low. Ho ...

View report

SP Angel Healthcare Conditions

AstraZeneca (AZN.L): FDA accepts NDA submission for selumetinib | Beximco Pharma: First quarter results show continued growth | Tissue Regenix Group plc (TRX.L): Update on loan agreement |

View report